|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119151 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-24 09:46:32 |
|
注册时间: Date of Registration: |
2026-02-24 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
产后盆腔肌筋膜疼痛的产科因素及其预测模型构建 |
|
Public title: |
Predictors and Model Development for Postpartum Pelvic Myofascial Pain |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
产后盆腔肌筋膜疼痛的产科因素及其预测模型构建 |
|
Scientific title: |
Predictors and Model Development for Postpartum Pelvic Myofascial Pain |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蔡月云 |
研究负责人: |
蔡月云 |
|
Applicant: |
Yueyun Cai |
Study leader: |
Yueyun Cai |
|
申请注册联系人电话: Applicant telephone: |
+86 596 208 9140 |
研究负责人电话:
Study leader's |
+86 596 208 9140 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
515691626@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
515691626@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省漳州市胜利路59号 |
研究负责人通讯地址: |
福建省漳州市胜利路59号 |
|
Applicant address: |
No. 59, Shengli Road, Zhangzhou City, Fujian Province |
Study leader's address: |
No. 59, Shengli Road, Zhangzhou City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建省漳州市医院 |
||
|
Applicant's institution: |
Zhangzhou Hospital, Fujian Province |
||
|
研究负责人所在单位: |
福建省漳州市医院 |
||
|
Affiliation of the Leader: |
Zhangzhou Hospital, Fujian Province |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023LWB197;漳医伦2025KYZ161号;漳医伦2025KYZ161-2号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省漳州市医院伦理委员会 |
||
|
Name of the ethic committee: |
Zhangzhou Hospital Ethics Committee of Fujian Province |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-10-10 00:00:00 | ||
|
伦理委员会联系人: |
蒋辉 |
||
|
Contact Name of the ethic committee: |
Hui Jiang |
||
|
伦理委员会联系地址: |
福建省漳州市胜利路59号 |
||
|
Contact Address of the ethic committee: |
No. 59, Shengli Road, Zhangzhou City, Fujian Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 596 208 2561 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建省漳州市医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhangzhou Affiliated Hospital of Fujian medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省漳州市胜利路59号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 59, Shengli Road, Zhangzhou City, Fujian Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建医科大学启航基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Fujian Medical University Qihang Foundation |
||||||||||||||||||||||
|
研究疾病: |
盆腔肌筋膜疼痛 |
||||||||||||||||||||||
|
Target disease: |
Myofascial pelvic pain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究拟进一步明确产后盆腔肌筋膜疼痛的产科因素,并首次基于这些明确后的产科因素,尝试构建能够预测产后盆腔肌筋膜疼痛的预测模型并验证其预测效能。本研究成果能够为产后盆腔肌筋膜疼痛的早期预警提供可靠工具,进而有助于对产妇实施早期盆腔肌筋膜疼痛的预防与治疗措施,进而有利于改善产妇的预后和生活治疗,具有重要的研究意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to further elucidate the obstetric factors contributing to postpartum MFPP (Maternal-Fetal/Perinatal Pathology) and, for the first time, construct and validate a predictive model based on these identified factors to assess its predictive performance. The findings of this research will provide a reliable tool for the early warning of postpartum MFPP, thereby facilitating the implementation of preventive and therapeutic interventions at an earlier stage. This advancement is expected to significantly improve maternal prognosis and quality of life, underscoring the critical scientific significance of this investigation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.于我院完成妊娠期间的产检并顺利分娩; 2.所有产妇在入组时均完善产科因素的登记; 3.产前无慢性盆腔痛病史; 4.对本研究内容知情,自愿参加并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Completed prenatal examinations during pregnancy and delivered smoothly at our hospital; 2. All pregnant women completed the registration of obstetric factors at the time of enrollment; 3. Had no history of chronic pelvic pain before pregnancy; 4. Were informed of the content of this study, voluntarily participated and signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.泌尿、生殖系统急性感染或结石等器质性疾病的产妇; 2.既往骨盆外伤史、盆腔手术史、盆腔肿瘤的产妇; 3.合并中枢神经系统疾病及坐骨神经痛等神经系统病史的产妇; 4.合并精神疾病或认知功能障碍,无法配合研究的产妇。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant women with acute infections or stones in the urinary and reproductive systems, or other organic diseases; 2. Pregnant women with a history of pelvic trauma, pelvic surgery, or pelvic tumors; 3. Pregnant women with a history of central nervous system diseases and sciatic nerve pain, etc. related to neurological disorders; 4. Pregnant women with mental disorders or cognitive dysfunction and unable to cooperate with the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-12-01 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |